Roxbury Financial’s Gilead Sciences GILD Stock Holding History

Roxbury Financial’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$120K	Sell	948 -44	-4%	-$5.8K	0.09%	132
2026 Q1	$138K	Buy	992 +6	+0.6%	+$840	0.12%	113
2025 Q4	$121K	Buy	986 +5	+0.5%	+$608	0.11%	120
2025 Q3	$109K	Buy	981 +7	+0.7%	+$796	0.1%	125
2025 Q2	$108K	Buy	974 +17	+2%	+$1.81K	0.11%	121
2025 Q1	$109K	Buy	957 +8	+0.8%	+$825	0.11%	117
2024 Q4	$87.9K	Buy	+949	New	+$85.4K	0.08%	122

Other funds holding GILD

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Roxbury Financial's GILD Position: Q2 2026 in Review

Roxbury Financial reduced its Gilead Sciences (GILD) stake by 4.4% in Q2 2026, selling an estimated $5.8K and leaving 948 shares worth $120K. The position accounts for 0.09% of the portfolio, ranked #132.

Roxbury Financial first reported a position in GILD in Q4 2024 and has held it in 7 quarters since. The position peaked at $138K in Q1 2026. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Roxbury Financial held 948 shares of Gilead Sciences worth $120K as of Q2 2026.
Roxbury Financial sold 44 Gilead Sciences shares in Q2 2026, an estimated $5.8K.
Gilead Sciences made up 0.09% of Roxbury Financial's portfolio in Q2 2026, its #132 holding.
Roxbury Financial first reported a position in Gilead Sciences in Q4 2024 and has held it in 7 quarters since.
Roxbury Financial's Gilead Sciences position peaked at $138K in Q1 2026.
690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Roxbury Financial's 13F filing for Q2 2026, filed 1 Jul 2026.